Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Read More…
Industry, Sector and Symbol
Industry Laboratory apparatus & furniture
Sub-IndustryN/A
SectorComputer and Technology
Phone631-694-9555
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$38.85 million
Profitability
Miscellaneous
Employees118
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Misonix (NASDAQ:MSON) Frequently Asked Questions
What is Misonix's stock symbol?
Misonix trades on the NASDAQ under the ticker symbol "MSON."
How were Misonix's earnings last quarter?
Misonix, Inc. (NASDAQ:MSON) released its quarterly earnings results on Wednesday, August, 14th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter. The medical equipment provider earned $9.75 million during the quarter. Misonix had a negative net margin of 19.01% and a negative return on equity of 25.99%. View Misonix's Earnings History.
When is Misonix's next earnings date?
What price target have analysts set for MSON?
2 brokers have issued 1 year target prices for Misonix's shares. Their forecasts range from $27.00 to $30.00. On average, they anticipate Misonix's stock price to reach $28.50 in the next year. This suggests a possible upside of 65.2% from the stock's current price. View Analyst Price Targets for Misonix.
What is the consensus analysts' recommendation for Misonix?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Misonix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Misonix.
Has Misonix been receiving favorable news coverage?
News articles about MSON stock have trended positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Misonix earned a daily sentiment score of 2.1 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Misonix.
Are investors shorting Misonix?
Misonix saw a drop in short interest in September. As of September 15th, there was short interest totalling 384,700 shares, a drop of 5.5% from the August 15th total of 406,900 shares. Based on an average daily volume of 64,000 shares, the short-interest ratio is currently 6.0 days. Currently, 4.8% of the shares of the company are short sold. View Misonix's Current Options Chain.
Who are some of Misonix's key competitors?
Some companies that are related to Misonix include Control4 (CTRL), CEVA (CEVA), Smart Global (SGH), Agilysys (AGYS), Emis Group (EMIS), TechTarget (TTGT), Ultra Clean (UCTT), QuinStreet (QNST), Jiayin Group (JFIN), Ribbon Communications (RBBN), Forrester Research (FORR), Ichor (ICHR), Tucows (TCX), Onespan (OSPN) and Simulations Plus (SLP).
What other stocks do shareholders of Misonix own?
Who are Misonix's key executives?
Misonix's management team includes the folowing people:
- Mr. Stavros George Vizirgianakis, Pres, CEO & Director (Age 49)
- Mr. Joseph P. Dwyer, CFO, Treasurer & Sec. (Age 63)
- Mr. Robert Scott Ludecker, Sr. VP of Global Sales & Marketing (Age 52)
- Ms. Sharon W. Klugewicz, Chief Operating Officer (Age 51)
- Mr. John J. Salerno, VP of Quality and Regulatory Affairs & Chief Compliance Officer (Age 64)
Who are Misonix's major shareholders?
Misonix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (0.56%). Company insiders that own Misonix stock include Christopher H Wright, Joseph J Brennan, Joseph P Dwyer, Patrick A Mcbrayer, Sharon W Klugewicz and Thomas M Patton. View Institutional Ownership Trends for Misonix.
Which major investors are selling Misonix stock?
MSON stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC. Company insiders that have sold Misonix company stock in the last year include Christopher H Wright and Joseph J Brennan. View Insider Buying and Selling for Misonix.
How do I buy shares of Misonix?
Shares of MSON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Misonix's stock price today?
One share of MSON stock can currently be purchased for approximately $17.25.
How big of a company is Misonix?
What is Misonix's official website?
How can I contact Misonix?
Misonix's mailing address is 1938 NEW HIGHWAY, FARMINGDALE NY, 11735. The medical equipment provider can be reached via phone at 631-694-9555.
MarketBeat Community Rating for Misonix (NASDAQ MSON)
MarketBeat's community ratings are surveys of what our community members think about Misonix and other stocks. Vote "Outperform" if you believe MSON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MSON will underperform the S&P 500 over the long term. You may vote once every thirty days.
